Advertisement

The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes

      Abstract

      Human preadipocytes and adipocytes are known to produce the proatherogenic factor PAI-1 and proinflammatory cytokines, and obesity was found to be state of increased adipose production of these factors. In the present study, we investigated the effect of rosuvastatin on the regulation of PAI-1 gene expression in human adipocytes. Human preadipocytes, adipocytes in primary culture and the SGBS cell line were used as cell models. Cells were transfected using various constructs and promoter activity was measured as luciferase activity. PAI-1 expression was measured by quantitative RT-PCR and ELISA. Rosuvastatin inhibited PAI-1 mRNA expression and secretion of the protein in a concentration-dependent manner. This effect was reversed by isoprenoids. Addition of MEK-inhibitors and NFκB inhibitors also reduced PAI-1 expression and PAI-1 promoter luciferase activity. Further experiments revealed that rosuvastatin down-regulated the MEKK-1 mediated activation of the PAI-1 promoter. In conclusion our data suggest that rosuvastatin inhibits PAI-1 expression and release from human adipocytes via a MEKK-1-dependent but not a NFκB-dependent mechanism.

      Abbreviations:

      Adip. (primary human adipocyte), da (dominant active), dn (dominant negative), FPP (farnesyl pyrophosphate), GGPP (geranylgeranyl pyrophosphate), IκB (inhibitor of NFκB), MAPK (mitogen-activated protein kinase), MEKK-1 (mitogen-activated protein kinase kinase kinase-1), NFκB (nuclear factor kappa B), PA (primary human preadipocyte), PAI-1 (plasminogen activation inhibitor), RSV (rosuvastatin)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hill J.O.
        • Wyatt H.R.
        • Reed G.W.
        • Peters J.C.
        Obesity and the environment: where do we go from here?.
        Science. 2003; 299: 853-855
        • Alessi M.C.
        • Juhan-Vague I.
        PAI-1 and the metabolic syndrome. Links, causes, and consequences.
        Arterioscler Thromb Vasc Biol. 2006; 26: 2200-2207
        • Skurk T.
        • Hauner H.
        Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1.
        Inter J Obes. 2004; 28: 1357-1364
        • Lijnen H.R.
        • Maquoi E.
        • Morange P.
        • et al.
        Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1.
        Arterioscler Thromb Vasc Biol. 2003; 23: 78-84
        • Ma L.J.
        • Mao S.L.
        • Taylor K.L.
        • et al.
        Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.
        Diabetes. 2004; 53: 336-346
        • Schafer K.
        • Fujisawa K.
        • Konstantinides S.
        • Loskutoff D.J.
        Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice.
        FASEB J. 2001; 15: 1840-1842
        • Dong J.
        • Fujii S.
        • Li H.
        • et al.
        Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-{delta}.
        Arterioscler Thromb Vasc Biol. 2005; 25: 1078-1084
        • Kleemann R.
        • Kooistra T.
        HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol.
        Curr Drug Targets Cardiovasc Haematol Disord. 2005; 5: 441-453
        • Markle A.
        • Nicholson A.
        Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells.
        J Cell Biochem. 2003; 90: 23-32
        • Swiatkowska A.
        • Cierniewski C.
        Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity.
        Jpn J Pharmacol. 2002; 90: 337-344
        • van Harmelen V.
        • Skurk T.
        • Rohrig K.
        • Hauner H.
        HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes.
        Horm Metab Res. 2003; 35: 466-470
        • Skurk T.
        • Hauner H.
        • Wabitsch M.
        Cultures of human adipose precursor cells.
        Methods Mol Biol. 2001; 155: 239-247
        • Aprath-Husmann I.
        • Rohrig H.
        • Gottschling-Zeller H.
        • et al.
        Effects of leptin on the differentiation and metabolism of human adipocytes.
        Int J Obes Relat Metab Disord. 2001; 25: 1465-1470
        • Wabitsch M.
        • Brenner R.
        • Menge C.
        • et al.
        Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation.
        Int J Obes Relat Metab Disord. 2001; 25: 8-15
        • Green H.
        • Meuth M.
        An established pre-adipose cell line and its differentiation in culture.
        Cell. 1976; 3: 127-133
        • Baumann B.
        • Kistler B.
        • Kirillov A.
        • Bergman Y.
        • Wirth T.
        The mutant plasmacytoma cell line S107 allows the identification of distinct pathways leading to NF-kappa B activation.
        J Biol Chem. 1998; 273: 11448-11455
        • Laumen H.
        • Nielsen P.
        • Wirth T.
        The BOB.1/OBF. 1 co-activator is essential for octamer-dependent transcription in B cells.
        Eur J Immunol. 2000; 30: 458-469
        • Hou B.
        • Eren M.
        • Painter C.A.
        • et al.
        Tumor necrosis factor {alpha} activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor {kappa}B site.
        J Biol Chem. 2004; 279: 18127-18136
        • Takeda K.
        • Ichiki T.
        • Tokunou T.
        • et al.
        Critical Role of rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression.
        Arterioscler Thromb Vasc Biol. 2001; 21: 868-873
        • Chen H.C.
        • Feener E.P.
        MEK1,2 response element mediates angiotensin II-stimulated plasminogen activator inhibitor-1 promoter activation.
        Blood. 2004; 103: 2636-2644
        • Aso Y.
        • Wakabayashi S.
        • Yamamoto R.
        • Matsutomo R.
        • Takebayashi K.
        • Inukai T.
        Metabolic syndrome accompanied by hypercholesterolemia Is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
        Diabetes Care. 2005; 28: 2211-2216
        • Festa A.
        • Williams K.
        • Tracy R.P.
        • Wagenknecht L.E.
        • Haffner S.M.
        Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
        Circulation. 2006;
        • Kanaya A.M.
        • Wassel Fyr C.
        • Vittinghoff E.
        • et al.
        Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
        Arch Intern Med. 2006; 166: 350-356
        • Bourcier T.
        • Libby P.
        HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.
        Arterioscler Thromb Vasc Biol. 2000; 20: 556-562
        • Lopez S.
        • Peiretti F.
        • Bonardo B.
        • Juhan-Vague I.
        • Nalbone G.
        Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells.
        Atherosclerosis. 2000; 152: 359-366
        • Morikawa S.
        • Takabe W.
        • Mataki C.
        • et al.
        The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC.
        J Atheroscler Thromb. 2002; 9: 178-183
        • Li J.Q.
        • Zhao S.P.
        • Li Q.Z.
        • et al.
        Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits.
        Clin Chim Acta. 2006;
        • Vulin A.I.
        • Stanley F.M.
        Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription.
        J Biol Chem. 2004; 279: 25172-25178
        • Landsberger M.
        • Wolff B.
        • Jantzen F.
        • et al.
        Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells.
        Atherosclerosis. 2007; 190: 43-52
        • Inoue I.
        • Itoh F.
        • Aoyagi S.
        • et al.
        Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.
        Biochem Biophys Res Commun. 2002; 290: 131-139
        • Hilgendorff A.
        • Muth H.
        • Parviz B.
        • et al.
        Statins differ in their ability to block NF-kappaB activation in human blood monocytes.
        Int J Clin Pharmacol Ther. 2003; 41: 397-401
        • Madonna R.
        • Di Napoli P.
        • Massaro M.
        • et al.
        Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts.
        J Biol Chem. 2005; 280: 13503-13511
        • Zelvyte I.
        • Dominaitiene R.
        • Crisby M.
        • Janciauskiene S.
        Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro.
        Pharmacol Res. 2002; 45: 147-154
        • Dichtl W.
        • Dulak J.
        • Frick M.
        • et al.
        HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
        Arterioscler Thromb Vasc Biol. 2003; 23: 58-63
        • Huwiler A.
        • Xin C.
        • Brust A.K.
        • Briner V.A.
        • Pfeilschifter J.
        Differential binding of ceramide to MEKK1 in glomerular endothelial and mesangial cells.
        Biochim Biophys Acta. 2004; 1636: 159-168
        • Kimura M.
        • Soeda S.
        • Oda M.
        • Ochiai T.K.T.
        • Ono N.
        • Shimeno H.
        Release of plasminogen activator inhibitor-1 from human astrocytes is regulated by intracellular ceramide.
        J Neurosci Res. 2000; 62: 781-788
        • Chen S.
        • Hu C.
        • Yang D.I.
        • et al.
        Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation.
        Ann NY Acad Sci. 2005; 1042: 357-364
        • Tousoulis D.
        • Antoniades C.
        • Bosinakou E.
        • et al.
        Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.
        Heart. 2005; 91: 27-31
        • Ludwig S.
        • Dharmalingam S.
        • Erickson-Nesmith S.
        • et al.
        Impact of simvastatin on hemostatic and fibrinolytic regulators in type 2 diabetes mellitus 1.
        Diabetes Res Clin Pract. 2005; 70: 110-118
        • Eriksson P.
        • Reynisdottir S.
        • Lonnqvist F.
        • Stemme V.
        • Hamsten A.
        • Arner P.
        Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals.
        Diabetologia. 1998; 41: 65-71
        • Liao J.K.
        Isoprenoids as mediators of the biological effects of statins.
        J Clin Invest. 2002; 110: 285-288
        • Kempe S.
        • Kestler H.
        • Lasar A.
        • Wirth T.
        NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program.
        Nucleic Acids Res. 2005; 33: 5308-5319